B. Riley Financial Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price target increased by B. Riley Financial from $97.00 to $129.00 in a research report released on Thursday, MarketBeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

Several other brokerages have also recently commented on LNTH. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Mizuho raised their target price on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $108.29.

Lantheus Stock Performance

Shares of Lantheus stock opened at $105.99 on Thursday. The company has a market capitalization of $6.90 billion, a PE ratio of 25.54 and a beta of -0.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The company has a 50-day simple moving average of $100.22 and a two-hundred day simple moving average of $82.74. Lantheus has a one year low of $47.25 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts expect that Lantheus will post 4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Western Wealth Management LLC acquired a new position in Lantheus during the first quarter worth $25,000. Smartleaf Asset Management LLC increased its holdings in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the period. Osterweis Capital Management Inc. purchased a new stake in Lantheus during the second quarter worth about $36,000. Finally, Bessemer Group Inc. lifted its position in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.